Qiagen Submits Second PMA for Therascreen KRAS Companion Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen today said that it has submitted a second Premarket Approval application to the US Food and Drug Administration for its therascreen KRAS RGQ PCR Kit for use a companion diagnostic with metastatic colorectal cancer drug Erbitux (cetuximab).

Erbitux is sold in the US by Bristol-Myers Squibb and Eli Lilly. Outside of the US and Canada, it is sold by Germany's Merck KGaA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.